These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 7746010)

  • 1. [Monoclonal antibodies and gram-negative bacterial sepsis: is their use really justified?].
    Alsar MJ; Sánchez-Palacios M
    Med Clin (Barc); 1993 Sep; 101(7):278. PubMed ID: 7746010
    [No Abstract]   [Full Text] [Related]  

  • 2. Monoclonal antibody therapy for gram-negative sepsis: principles, applications, and controversies.
    Mehra IV; Gottlieb JE; Nash DB
    Pharmacotherapy; 1993; 13(2):128-34. PubMed ID: 8469619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal therapy for bacteremia and sepsis.
    Guglielmo J; Wiener-Kronish JP
    West J Med; 1992 Aug; 157(2):174. PubMed ID: 1441476
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparison of the efficacy, safety, and therapeutic usage of HA-1A and E5 in the treatment of gram-negative sepsis.
    Quintiliani R; Cooper B; Maderazo E; Nightingale C
    Hosp Formul; 1992 Jan; 27(1):49-52, 54, 57-60. PubMed ID: 10116116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human monoclonal antibodies in sepsis.
    de Koning J; Westendorp RG
    Neth J Med; 1991 Oct; 39(3-4):129-30. PubMed ID: 1791872
    [No Abstract]   [Full Text] [Related]  

  • 6. Monoclonal antibodies for gram-negative sepsis.
    Med Lett Drugs Ther; 1991 Nov; 33(856):103-4. PubMed ID: 1943976
    [No Abstract]   [Full Text] [Related]  

  • 7. Pilot study of anti-lipopolysaccharide human monoclonal antibody MAB-T88 in patients with gram-negative sepsis.
    Daifuku R; Panacek EA; Haenftling K; Swenson WK; Prescott AW; Johnson JL
    Hum Antibodies Hybridomas; 1993 Jan; 4(1):36-9. PubMed ID: 8431557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Criteria for use of antiendotoxin monoclonal antibodies (HA-1A and E5) in adult and pediatric inpatients.
    Shepherd MF
    Clin Pharm; 1992 Mar; 11(3):257-60. PubMed ID: 1611816
    [No Abstract]   [Full Text] [Related]  

  • 9. [Monoclonal antibodies in the treatment of sepsis caused by Gram-negative microorganisms].
    Otero AJ; Linares M
    Rev Cubana Med Trop; 1998; 50(1):31-5. PubMed ID: 9842265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal antibodies to endotoxin in the management of sepsis.
    Fang KC
    West J Med; 1993 Apr; 158(4):393-9. PubMed ID: 8317126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy of gram-negative septicemia.
    van Deventer SJ
    Prog Clin Biol Res; 1991; 367():135-9. PubMed ID: 1924423
    [No Abstract]   [Full Text] [Related]  

  • 12. Findings halt clinical trials of centoxin.
    Wagner M
    Mod Healthc; 1993 Jan; 23(4):16. PubMed ID: 10123669
    [No Abstract]   [Full Text] [Related]  

  • 13. [Preventive interruption of the administration of HA-1A monoclonal antibody against endotoxin].
    Torrabadella de Reynoso P; Trilla A; Salgado A; Ribas J
    Med Clin (Barc); 1993 Apr; 100(13):518. PubMed ID: 8479241
    [No Abstract]   [Full Text] [Related]  

  • 14. Projected impact of monoclonal anti-endotoxin antibody therapy.
    Bates DW; Lee TH
    Arch Intern Med; 1994 Jun; 154(11):1241-9. PubMed ID: 8203991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel immunotherapeutic approaches to the treatment of infections caused by Gram-negative bacteria.
    Palliyil S; Broadbent ID
    Curr Opin Pharmacol; 2009 Oct; 9(5):566-70. PubMed ID: 19726227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of HA-1A treatment for patients with sepsis.
    van Hout BA; Birnie E; Redekop WK; Lorijn RH; Bossuyt PM; Rutten FF
    Prog Clin Biol Res; 1994; 388():435-43. PubMed ID: 7831376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Introduction of immunotherapeutic agents in clinical practice; current status concerning anti-endotoxin antibody HA-1A in the control of sepsis].
    van Deventer SJ; van der Linden CJ; Roord JJ; Schellekens H; Schellekens JF
    Ned Tijdschr Geneeskd; 1993 Feb; 137(7):334-6. PubMed ID: 8437630
    [No Abstract]   [Full Text] [Related]  

  • 18. New immunotherapies for sepsis.
    Young LS; Wenzel RP
    Proc Assoc Am Physicians; 1995 Oct; 107(3):361-4. PubMed ID: 8608423
    [No Abstract]   [Full Text] [Related]  

  • 19. Therapies for sepsis. Emerging therapies for sepsis and septic shock.
    Abraham E
    West J Med; 1997 Mar; 166(3):195-200. PubMed ID: 9143195
    [No Abstract]   [Full Text] [Related]  

  • 20. Multicenter evaluation of a human monoclonal antibody to Enterobacteriaceae common antigen in patients with Gram-negative sepsis.
    Albertson TE; Panacek EA; MacArthur RD; Johnson SB; Benjamin E; Matuschak GM; Zaloga G; Maki D; Silverstein J; Tobias JK; Haenftling K; Black G; Cowens JW;
    Crit Care Med; 2003 Feb; 31(2):419-27. PubMed ID: 12576946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.